Hormos signs license agreement with Linnea on HMRlignan
HMRlignan is a highly purified lignan, which effectively elevates the enterolactone level already at milligram doses.
22/04/05 Hormos Medical Corporation has signed a world-wide license agreement for its dietary supplement ingredient HMRlignan with the Swiss botanical ingredient manufacturing company Linnea SA.
HMRlignan is a plant lignan, 7-hydroxymatairesinol, isolated and purified from Norway spruce (picea abies). Lignans are generally classified as phytoestrogens, compounds that in humans have a weak estrogen like activity. In humans 7-hydroxymatairesinol is converted into mammalian lignan, enterolactone. Low intake of lignan and/or low enterolactone serum levels have in epidemiological studies been shown to be associated with increased risk of certain hormone dependent health conditions, including breast cancer and cardiovascular disease. In other studies phytoestrogens have been shown to alleviate menopausal symptoms.
HMRlignan is a highly purified lignan, which effectively elevates the enterolactone level already at milligram doses. In May 2004 Hormos obtained new dietary ingredient (NDI) clearance from the FDA, which allows HMRlignan containing dietary supplements to be marketed in the USA. HMRlignan is the first, and to date only commercially available high purity lignan product.
